Overview

Ticagrelor With Low-dose Versus Regular Aspirin in Patients With Acute Coronary Syndrome (ACS) at High-Risk for Ischemia After Percutaneous Coronary Intervention

Status:
Not yet recruiting

Trial end date:
2023-02-01

Target enrollment:

Participant gender:

Summary

The present study is aimed to compare the safety and efficacy of Ticagrelor with low-dose Aspirin versus standard dual anti-platelet therapy (DAPT) in patients with acute coronary syndrome (ACS) at high risk for ischemic events after percutaneous coronary intervention (PCI) and stent implantation.

Phase:

Phase 3

Details

Lead Sponsor:

Fu Wai Hospital, Beijing, China

Treatments:

Aspirin
Ticagrelor